Clinical Trial: Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Therapeutic Effect Between Quetiapine and Haloperidol on the Treatment of Methamphetamine - Induced Psychosis
Brief Summary: The aims of this study are to compare the antipsychotic and adverse events of quetiapine, an atypical antipsychotic drug, to haloperidol, a standard treatment for primary psychotic disorder, in individuals with MAP.
Detailed Summary: Eighty individuals with MAP will be randomly assigned into two treatment groups, i.e. treatment with quetiapine and haloperidol. The quetiapine group will receive quetiapine at least 100 mg per day and the haloperidol group will receive haloperidol at least 2 mg per day orally once a day for four weeks. The doses will be increased every 5 days until no psychotic symptom is observed from the Positive and Negative Syndrome Scale. Common antipsychotic adverse events will be checked and documented daily.
Sponsor: Chulalongkorn University
Current Primary Outcome:
- Positive and Negative Syndrome Scale [ Time Frame: Every day in Week 1. ]
- Positive and Negative Syndrome Scale [ Time Frame: Every two days in Week 2 and 3. ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Antipsychotic Adverse Event Form [ Time Frame: Every day for three weeks. ]
Original Secondary Outcome: Same as current
Information By: Chulalongkorn University
Dates:
Date Received: September 2, 2013
Date Started: March 2010
Date Completion:
Last Updated: September 5, 2013
Last Verified: September 2013
